Board of Directors
Dr. Martin Roland Jensen – Chairman
Dr. Martin Roland Jensen has extensive leadership experience from the biopharmaceutical industry and as a serial entrepreneur has founded and co-founded several biotech companies. He also has extensive experience with scientific work, mainly in immunology, cell biology and development of cancer vaccines. Dr. Jensen has a doctorate in cell and molecular biology from the University of Copenhagen.
Dr. Jensen is a co-founder of ExpreS2ion Biotechnologies ApS
Dr. Jensen has been a board member since 2010 and has besides his ownership in ExpreS2ion Holding ApS (see below), no dependent relationships with the management group nor to any other major shareholders.
Shares: Dr. Jensen owns 32.22% of the founder-owned company ExpreS2ion Holding ApS, which owns 1,744,370 (6.32%) of the shares in ExpreS2ion Biotech Holding AB. Dr. Jensen, through his holding company Medic-Advice Holding ApS, owns 46,290 shares. In addition, Dr. Jensen privately owns 209,436 shares in ExpreS2ion Biotech Holding AB.
Warrants: Dr. Jensen owns 46,290 warrants through his holding company Medic-Advise Holding ApS.
Dr. Allan Rosetzsky – Board Member
Dr. Allan Rosetzsky graduated as a Doctor of Medicine from the University of Copenhagen in 1973. Dr Rosetzsky followingly worked in the Danish health care system for years before holding several leading positions within the drug development of the Rhone-Poulenc Group during which he received General Management education at Ashridge Management College in the UK.
For five years he was based in Paris with worldwide responsibilities. In addition, he has founded, developed and run the clinical development company, KLIFO, an internationally renowned Danish clinical contract research company. Dr. Rosetzsky is furthermore an active member of the Business Angels Öresund.
Dr. Rosetzsky has been a board member since 2010 and has no dependent relationships to the management group nor to any major shareholders.
Since 2020, he also serves as board member at AdaptVac ApS.
Shares: Through his 100% owned company AR Consult, Dr. Rosetzsky owns 1,328,309 shares in ExpreS2ion Biotech Holding AB. In addition, Dr. Rosetzsky privately owns 34,000 shares in ExpreS2ion Biotech Holding AB.
Warrants: Through his 100% owned company AR Consult, Dr. Rosetzsky owns 22,200 warrants.
Gitte Pedersen – Board Member
Gitte Pedersen graduated as a Master from the Danish Technological University with top scores in Biochemical Engineering and she holds a bachelor’s degree in International Trade. She has more than 20 years of management-level experience in the biotech/pharma industry in Europe, USA and India, ten years in large biotech in a number of executive positions, as head of marketing strategy and sales, development of biologics manufacturing processes, scale-up as well as R&D, with six issued patents.
Gitte Pedersen established Proximity Venture Advisors in 1997 providing executive advice for several biotech and governmental institutions, resulting in numerous licensing and equity deals with companies such as GlaxoSmithKline, Johnson & Johnson, MSD with an aggregated value more than $1 billion. She is the founder of and on the board of Genomic Expression and Legomics (spin out of Genomic Expression), and Female Equity and Ethel Walker (not for profits).
Gitte Pedersen is an independent member of the Board and holds 25,200 shares in the Company.
Jakob Knudsen – Board Member
Jakob Knudsen is the CEO of Virogates A/S (NASDAQ “VIRO”), an international diagnostics company located in Denmark and is, in addition, a non-executive director in PV Fonden (DK). He holds a Master of Law from the University of Copenhagen, DK, and an MBA from Imperial College, UK. Following his graduation in 1994, Jakob Knudsen has built up extensive experience in commercial operations, including business development, marketing and finance.
He has held various positions at ALK-Abelló A/S, a listed mid-sized biotechnology company in Denmark, where he a.o. headed Corporate Business Development. Furthermore, he has held positions as CCO and CFO at the Danish pharmaceutical company Egalet Ltd.
Jakob Knudsen is an independent member of the board and holds 35,000 shares in the company.